ARTICLE | Clinical News

Gastrin immunogen data

March 28, 1994 8:00 AM UTC

APHT (Woodland, Calif.) announced results of U.K. safety testing in its Phase I trial, saying that the immunogen was well tolerated and produced antibody titers in excess of circulating gastrin 17, reducing stomach acid by 90 percent.

Gastrin-17 is the form of gastrin which controls stomach acid; it is also a growth factor for colorectal cancer, the company said. ...